



**Book Chapter:**

1. **Giroto JE.** Central Nervous System Infections. In: Sutton SS, eds. McGraw-Hills Naplex Review Guide. New York, NY: McGraw Hill Medical; 2011: 215-222.

**Research:**

1. Phung OJ, Coleman CI, Baker EL, Scholle JM, **Giroto JE**, Makanji SS, Chen WT, Talati R, Kluger J, White CM. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. *Pediatrics*. 2010 Nov;126(5):e1211-26. Epub 2010 Oct 4.
2. Courter JD, Baker WL, Nowak KS, Smogowicz LA, Desjardins LL, Coleman CI, **Giroto JE.** Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis. *Ann Pharmacotherapy*. 2010 Mar;44 (3):471-478. Epub 2010 Feb 11.
3. Courter JD, Kuti JL, **Giroto JE**, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using extended infusions in the pediatric population. *Pediatric Blood and Cancer*. 2009:May 6. {Epub ahead of print}
4. St. Germain RM, Kuti JK, Doern GV, **Giroto JE**, Nicolau DP. Pharmacodynamic Target Attainment of Oral  $\beta$ -lactams for the Empiric Treatment of Acute Otitis Media in Children. *Paediatr Drugs*. 2008;10(5):329-35.
5. Peter J. Krause, Benjamin E. Gewurz, David Hill, Francisco M. Marty, Edouard Vannier, Ivo M. Foppa, Richard R. Furman, Ellen Neuhaus, Gail Skowron, Shaili Gupta, Carlo McCalla, Edward L. Pesanti, Mary Young, Donald Heiman, Gunther Hsue, Jeffrey A. Gelfand, Gary P. Wormser, John Dickason, Frank J. Bia, Barry Hartman, Sam R. Telford III, Diane Christianson, Kenneth Dardick, Morton Coleman, **Jennifer E. Giroto**, Andrew Spielman. Persistent and Relapsing Babesiosis in Immunocompromised Patients. *Clin Infect Dis* 2008 Feb 1;46(3):370-6.
6. **Ellis JM**, Rivera L, Reyes G, Castillo F, Marte P, Tejada M, Salazar JC. Cefepime cerebrospinal fluid concentrations in neonatal bacterial meningitis. *Ann Pharmacother* 2007 May;41(5):900-1
7. **Ellis JM**, Kuti JL, Nicolau DP. Pharmacodynamic Evaluation of

Meropenem (MER) and Cefotaxime (CTX) for Pediatric Meningitis – A Report from the OPTAMA Program, *Pediatric Drugs*, 2006;8:131-138.

8. **Ellis JM**, Kuti JL, Nicolau DP. Pharmacodynamic Assessment of Antimicrobial Agents Against *Pseudomonas aeruginosa* in Children – A Report from the OPTAMA program, *Clinical Therapeutics*, 2005;11; 1820-1830.

**Position Statement:**

1. Johnson PN, Miller JL, Boucher EA, Lubsch L, **Giroto JE**, Pesaturo KA, Lee B, on behalf of the PPAG Advocacy Committee. Medication dosing in overweight and obese children. Pediatric Pharmacy Advocacy Group Position Statement. March 2010.

**Review Articles:**

1. Cutting PE. **Giroto JE**. 2011 Immunization “CatchUp” *Pharmacy Journal of New England*. Spring 2011.
2. Hershgordon C. **Giroto J**. Vaccine Update 2009 – 2010. *Pharmacy Journal of New England*. Nov 2010.
3. Courter JD, Teevan CJ, Li MH, **Giroto JE**, Salazar JC. Role of tipranavir in treatment of patients with multidrug-resistant HIV. *Ther Clin Risk Manag*. 2010 Oct 5;6:431-41.
4. **Giroto JE**. Etravavirine: A unique non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1. *Formulary* 2010;45:78-83;101-103.
5. **Giroto JE**. Immunization Update: What's New With the Flu? *Pharmacy Journal of New England*. Fall 2008;5(4):18.
6. Courter JD, **Giroto JE**, Salazar JC. Tipranavir: A new protease inhibitor for the pediatric population. *Expert Rev Anti Infect Ther*. 2008 Dec;6(6):797-803.
7. St. Germain RM, **Giroto JE\***. A review of clinical experience with newer antifungals in children. *Journal of Pediatric Pharmacy and Therapeutics. J Pediatric Pharmacol Ther*; 2008 13:124-140. (\*corresponding author)
8. **Giroto JE**. Maraviroc: The first CCR5 antagonist for the treatment of HIV. *Formulary Journal* 2007 October.



9. St. Germain RM, **Ellis JM**.<sup>\*</sup> Anidulafungin: An echinocandin for the treatment of *Candida* infections. *Formulary* 2006;41:387–403.
10. **Ellis JM**, Ross JW. Tipranavir: A Protease Inhibitor of a Nonpeptidic Nature. *Formulary*, 2005;40:104-113. (*\*Corresponding Author*)
11. **Ellis JM**, Reilly JC, Salazar JC. Influenza vaccination for the pediatric patient: A focus on the new intranasal, cold-adapted, live attenuated vaccine. *The Journal of Pediatric Pharmacology and Therapeutics*, 2004;9:104-109.
12. **Ellis JM**, Ross JW, Coleman CI. Fosamprenavir: A Novel Protease Inhibitor and Prodrug of Amprenavir. *Formulary*, 2004;39:151-160.
13. **Ellis JM**, Reddy P. Effects of Panax Ginseng on Quality of Life. *Annals of Pharmacotherapy*. 2002;36:357-379.

**Case Reports:**

1. Courter JD, **Giroto JE**, Lobato MN, Orcutt D, Burke M, Feder HM Jr, Krause PJ, Cohen-Abbo A, Salazar JC. Intravenous streptomycin treatment for an infant with Mycobacterium tuberculosis meningitis. *Pharmacotherapy* 2010 Nov;30: 481e–484e.
2. St Germain RM, Yigit S, Wells L, **Ellis JM**<sup>\*</sup>, Salazar JC. Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV infected adolescent. *AIDS Patient Care STDS* 2007;21(7):526. (*\*Corresponding Author*)

**Parent Information Leaflets:**

1. Mital N, **Giroto JE**. What Parents Should Know about Prevnar 13. Parent information leaflet for Kidsmeds. Available at: <http://www.kidsmeds.info/en/art/78/>
2. Tom-Revzon C, Klein K, **Giroto JE**. Don't let the Ticks Bite. Parent Information Leaflet. Available on [www.ppag.org](http://www.ppag.org) under Kids Meds Spring Topics. March 2010.

**Posters/Platform Presentations (Note maiden name is Ellis)**

1. Courter JD, Kuti JL, **Giroto JE**, Nicolau DP. Optimizing bactericidal exposure for  $\beta$ -lactams using extended infusions in the pediatric population. 2009 ACCP/ESCP International Congress on Clinical Pharmacy April 2009 Orlando, FL Poster 332.
2. Dugan SE, Courter JD, **Giroto JE**. Is single dose intramuscular ceftriaxone equivalent to standard oral first line treatments for children with acute otitis media? 43<sup>RD</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting Orlando FL Dec 2008 Poster P232E.
3. Courter JD, **Giroto JE**. Amoxicillin/clavulanate vs. guideline recommended cephalosporins for acute otitis media: a meta-analysis. 43<sup>RD</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting Orlando FL Dec 2008 Poster P227E.
4. Courter JD, Baker WL, Nowak KS, Smogowica LA, Coleman CI, **Giroto JE**. Are macrolides as efficacious as guideline recommended antibiotics in the first-line treatment of children with acute otitis media? A meta-analysis. 48<sup>TH</sup> Annual ICAAC / 46<sup>TH</sup> Annual IDSA October 2008, Washington DC. Poster Number 2035.
5. Courter JD, Lamb K, **Giroto JE**. Cefuroxime Axetil And Amoxicillin/Clavulanate for *Streptococcus Pneumoniae* Acute Otitis Media. Pediatric Pharmacy Advocacy Group Annual Meeting September 2008. Baltimore MD.
6. St. Germain RM, Matson KL, Ford JS, McCabe T, Low J, **Giroto JE** (corresponding author). Impact of appropriate antibiotic utilization on clinical outcomes in complicated skin and soft tissue infections (cSSTIs) in children. Pediatric Pharmacy Advocacy Group Annual Meeting September 2007. Portsmouth VA
7. St. Germain RM, Crudi L, **Giroto JE** (corresponding author). Improved use of antibiotics resulting from implementation of febrile neutropenia order set. Pediatric Pharmacy Advocacy Group Annual Meeting September 2007. Portsmouth VA



8. St. Germain RM, Kuti JL, Doern GV, **Giroto JE**, Nicolau DP. Pharmacodynamic Target Attainment of Oral Beta-lactams for the Empiric Treatment of Acute Otitis Media in Children. Pediatric Pharmacy Advocacy Group Annual Meeting September 2007. Portsmouth VA
9. Hooker SE, **Giroto JE** (corresponding author). Survey evaluating pediatric education and self-efficacy of community pharmacists in Connecticut: A pilot study. Pediatric Pharmacy Advocacy Group Annual Meeting September 2007. Portsmouth VA
10. St. Germain RM, **Ellis JM**. Empiric monotherapy for febrile neutropenia in children: a meta-analysis. 2007 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Memphis, TN, Poster # 75. April 2007.
11. Bissonnette C, St. Germain RM, **Ellis JM**. Does Appropriate Antibiotic Therapy Affect Hospital Duration for Methicillin-Resistant *Staphylococcus aureus* Infections in Children? 41st American Society of Health-System Pharmacists Midyear Clinical Meeting, Anaheim, CA. December 2006. SP#55.
12. St. Germain RM, Ford J, Matson KL, Low J, **Ellis JM**. Impact of inappropriate antibiotic therapy on complicated skin and soft tissue infections (cSSTIs) in children. 41<sup>st</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting, Anaheim, CA December 2006. RP#651.
13. St. Germain RM, Lucini SE, **Ellis JM\***, Coleman CI, Salazar JC. *Dyslipidemia differences among protease inhibitors (PIs) in children*. 2006 Annual Meeting of the American College of Clinical Pharmacy. St. Louis, MO, Poster #187. October 2006. (\*Corresponding Author)
14. Hooker SE, **Ellis JM\***. Survey Evaluating Education and Self-Efficacy Of Community Pharmacists In Connecticut: Methods. "Catch the Wave" Connecticut Society of Health Systems Pharmacists, Annual Meeting, October 2006.
15. St. Germain, **Ellis JM**. Preliminary evaluation of appropriate linezolid use in pediatric patients. 40<sup>th</sup> Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV. December 2005.



16. Boschetto D, **Ellis JM**. *Preliminary evaluation of empiric antibiotic treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections in hospitalized pediatric patients*. 40<sup>th</sup> Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV. December 2005.
17. Lucini SE, **Ellis JM**, Salazar JC. Adverse effects of protease inhibitors in pediatric and adolescent patients. 40<sup>th</sup> Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV. December 2005
18. Lucini SE, Sahni J, Coleman CI, **Ellis JM**. *A Meta-Analysis Evaluating Differences in Cholesterol and Triglyceride Elevation Between Protease Inhibitors in Children*. Pediatric Pharmacy Advocacy Group – Annual Meeting, Chicago, IL, October 2005.
19. **Ellis JM**, Kuti JL, Nicolau DP. *Pharmacodynamics of Meropenem (MER) and Cefotaxime (CTX) for Pediatric Meningitis - A Report from the OPTAMA Program*. Joint Meeting of the Pediatric Academic Society and the Society for Pediatric Research, Washington, DC May 2005.
20. Sykes RB, Sahni J, **Ellis JM\***, Kuti JL. *Retrospective Comparison of Lipid Amphotericin B Complex (ABLC) and Liposomal Amphotericin B (L-AMB) in the Pediatric Population*. American College of Clinical Pharmacy – Spring Practice and Research Forum, Myrtle Beach, SC April 2005, Abstract 113. Available in *Pharmacotherapy* 2005;25:469. (\*Honors advisor & Corresponding author)
21. **Ellis JM**, Kuti JL, Nicolau DP. *Pharmacodynamics (PD) of Antimicrobials Against Gram Negative Bacteria in Pediatric Patients - A Report from the OPTAMA Program*. American College of Clinical Pharmacy – Annual meeting, Dallas, TX October 2004, abstract 266E. (Encore presentation)
22. Sykes RB, Sahni J, **Ellis JM\***, Kuti JL. *Comparison of Lipid Amphotericin B Complex (ABLC) and Liposomal Amphotericin B (L-AMB) in a Retrospective Cohort of Pediatric Patients*. The 26th Annual Pharmacy Student Research Conference--Eastern States, Morgantown, WV October 2004.
23. **Ellis JM**, Rivera L, Reyes G, Castilo F, Marte P, Tejada M, Salazar JC.



- Cefepime Cerebrospinal Fluid (CSF) Concentrations in Neonatal Bacterial Meningitis.* 13<sup>th</sup> Annual PPAG Conference, St Petersburg, FL October 2004.
24. Sykes RB, **Ellis JM\***, Kuti JL. *The Safety of Lipid Amphotericin B Complex (ABL-C) and Liposomal Amphotericin B (L-AMB) in a Retrospective Cohort of Pediatric Patients.* "Catch the Wave" Connecticut Society of Health Systems Pharmacists, Annual Meeting, Farmington, CT October 2004.
25. **Ellis JM**, Kuti JL, Nicolau DP. *Pharmacodynamics (PD) of Antimicrobials Against Gram Negative Bacteria in Pediatric Patients - A Report from the OPTAMA Program.* Infectious Disease Society of America, Boston, MA October 2004, abstract 315.
26. **Ellis JM**, Kuti JL, Nicolau DP. *Pharmacodynamics of Antimicrobials against Streptococcus pneumoniae (SP) in Pediatric Patients - A Report from the OPTAMA Program.* Infectious Disease Society of America, Boston, MA October 2004, abstract 314.
27. **Ellis JM**, Rivera L, Reyes G, Castilo F, Marte P, Tejada M, Salazar JC. *Cefepime Concentrations in Neonatal Bacterial Meningitis.* Joint meeting of the Pediatric Academic Society and the Society for Pediatric Research, San Francisco, CA, May 2004, abstract 233. Available in Pediatric Research Supplement: April 2004.
28. **Ellis JM**, Gura KM, Patterson A, Neufeld E. *Development and Validation of Guidelines for Enoxaparin Use in High Risk Pediatric Patients.* Joint meetings of the American Society of Pediatric Hematology/Oncology, Pediatric Academic Society, and the Society for Pediatric Research, San Francisco, CA, May 2004, abstract 308. Available in Pediatric Blood and Cancer: 2004:42(6); 505.
29. **Ellis JM**, Gura KM, Patterson A, Neufeld E. *Further Development of Low Molecular Weight Heparin Guidelines for Pediatric Patients: Addressing the Deficiencies of the ACCP Consensus Conference on Antithrombotic Therapy.* The Eastern States Residency Conference, Baltimore, MD, May 2003.



30. **Ellis JM**, Gura KM, Patterson A, Neufeld E. *A Retrospective Review of Pediatric Enoxaparin Dosing & Monitoring*. The 37<sup>th</sup> Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Atlanta, GA, Dec 2002.

31. **Ellis JM**, Reddy P. *The Effects of Panax Ginseng on Health-Related Quality of Life*. The 36<sup>th</sup> Midyear Clinical Meeting of the American Society of Health System Pharmacists, New Orleans, LA, Dec 2001.



A chapter book is a category designated as appropriate for children who have learned to read, but are in the early stages of reading. Chapter books often still have drawings or pictures in them, but unlike a picture book, which is designed for very young children, a chapter book typically has pages without pictures also. A chapter book is comprised of several chapters, but they are very short, usually only a few pages in length.